Fenwick is representing Amunix, an immuno-oncology company, in its pending acquisition by Sanofi, a global biopharmaceutical company.
The acquisition will help Sanofi accelerate its efforts to expand its contributions to medicines for oncology patients and highlights its commitment to investing in research and discovery platforms. Under the terms of the agreement, Sanofi will acquire Amunix for an upfront payment of approximately $1 billion and up to $225 million upon achievement of certain future development milestones. The transaction is expected to close by the end of the first quarter of 2022, subject to customary closing conditions. More information can be obtained from Sanofi’s announcement.
The Fenwick transaction team includes corporate partners Effie Toshav, Doug Cogen, David Michaels and Amanda Rose, associates Christopher Gorman and Min Ju Park and law clerk Shannon Lieu; executive compensation & employee benefits partner Nancy Chen and associate Christophe Delrieu; technology transactions partner Stefano Quintini and associates Sophia Chen, Jefferson Lin, Kehl Sink, Trisha Hilder, and Monica Kim, staff attorneys Amy Brown, Jalila Sparks and Margaret Nguyen and law clerk Sarah Meyers; and intellectual property litigation law clerk Diana Buck.